Clinics in South Dakota
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What South Dakota law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.
South Dakota at a glance
- Pharmacy regulator
- South Dakota Board of Pharmacy (South Dakota Department of Health)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Clinics serving South Dakota
No verified clinics serving South Dakota are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Peptide access rules in South Dakota
Yes. A South Dakota resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a South Dakota-licensed prescriber, including through telehealth under SDCL chapter 34-52, and can obtain a compounded peptide when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the South Dakota Board of Pharmacy, including a licensed nonresident pharmacy. SDCL 34-52-3 requires a proper provider-patient relationship with a diagnosis reached through acceptable medical practices, SDCL 34-52-5 requires a real-time audio and video exam whenever in-person care would call for a face-to-face visit, and South Dakota has no state bulks list, so peptide compounding eligibility follows the FDA framework. [1] [2] [3] [4] [5] [6]
Compounded GLP-1 access in South Dakota
South Dakota has not published a state rule that is looser than FDA policy. Because many South Dakota patients use mail order, confirming that the dispensing pharmacy holds a South Dakota nonresident license is the main practical check. [1] [3] [7]
Research use only sellers in South Dakota
SDCL chapter 36-11 reserves dispensing of prescription drugs to licensed pharmacies and pharmacists, so shipping "research use only" injectable peptides to South Dakota consumers is not a licensed pharmacy activity. [3] [8]
How to check a clinic in South Dakota
- Confirm the prescribing clinician's license with the South Dakota medical or nursing board.
- Ask which pharmacy compounds or dispenses the peptide and check it in the South Dakota Board of Pharmacy (South Dakota Department of Health) license lookup. [1] [3] [4] [5] [6]
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in South Dakota. [3] [8]
Common questions in South Dakota
Can I get a GLP-1 prescription in South Dakota through telehealth?
Yes, from a provider licensed in South Dakota (or employed by a facility listed in SDCL 34-52-2) who first establishes a proper provider-patient relationship under SDCL 34-52-3. That relationship requires identity verification, consent, a diagnosis based on examination and any needed tests, a discussion of options, and follow-up care. SDCL 34-52-5 also requires a real-time audio and video examination whenever the same care in person would call for a face-to-face visit. [2]
Does South Dakota allow prescribing from an online questionnaire?
South Dakota law does not settle this for drugs that are not controlled substances. SDCL 34-52-6 bars prescribing a controlled substance solely in response to an internet questionnaire or consult, including by telephone, without a proper provider-patient relationship. GLP-1 drugs are not controlled, so that bar does not reach them. SDCL 34-52-3 still requires a proper relationship with a diagnosis reached through acceptable medical practices, and SDCL 34-52-5 requires a real-time audio and video examination whenever the same care in person would call for a face-to-face visit. [2]
Sources
- [1]South Dakota Board of Pharmacy (South Dakota Department of Health)
- [2]South Dakota Codified Laws chapter 34-52, Telehealth utilization by health care professionals
- [3]South Dakota Codified Laws chapter 36-11, Pharmacists and pharmacies (including nonresident pharmacy licensure, 36-11-19.2 and 36-11-19.3)
- [4]South Dakota Codified Laws 36-11-19.3, Nonresident pharmacy licensure
- [5]Administrative Rules of South Dakota chapter 20:51:31, Compounding practices (amended effective September 15, 2025)
- [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [7]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [8]21 U.S.C. 331, Prohibited acts